论文部分内容阅读
新生儿呼吸窘迫综合征(neonatal respiratory distress syndrome,NRDS)是导致早产儿死亡的主要原因之一。目前,临床普遍采取鼻塞式持续气道正压通气(NCPAP)联合肺表面活性物质(PS)治疗NRDS,并且取得了较为理想的疗效,促进了早产儿NRDS死亡率的下降[1]。但作为基层医院使用PS受到限制,故可以通过调节NCPAP呼气末正压发挥更加理想的作用,避免气管插管机械通气的应用。我科采用NCPAP治疗极低出生体质量早产儿NRDS 46例,效果较好,现报道如下。
Neonatal respiratory distress syndrome (NRDS) is one of the major causes of death in premature infants. Currently, nasal continuous positive airway pressure (NCPAP) and pulmonary surfactant (PS) are commonly used in the treatment of NRDS, and have achieved satisfactory therapeutic effect and have contributed to the decline of NRDS mortality in preterm infants [1]. However, the use of PS as a primary hospital is limited, so NCPAP can be adjusted by positive end-expiratory pressure to play a more ideal role in avoiding endotracheal intubation and mechanical ventilation. NRCAP treatment of low birth weight preterm children with NCP 46 46 cases, the effect is better, are reported below.